



# PEPFAR

U.S. President's Emergency Plan for AIDS Relief

# Advanced Disease Management and TB

PEPFAR Mozambique | March 8, 2022

Presenters:

Dércio Filimão, USAID Senior HIV/AIDS Treatment Advisor  
(Back-up: Nidze Guiloviça)


Yagna Varajidas, CDC HIV/TB Specialist (Back-up: James Cowan)

**19 YEARS OF SAVING LIVES THROUGH AMERICAN GENEROSITY AND PARTNERSHIPS**

# Advanced HIV Disease Management

# Despite Improved ART Coverage and VLS, AHD in Mozambique is Relatively High

## Trend in CD4 at initiation 2010-21



Source: MozArt FY2021 Q4

## AHD

- Around 50% of patients with low CD4 at ART initiation are asymptomatic <sup>(1)</sup>
- People presenting with advanced HIV disease are at high risk of death, even after starting ART<sup>(2)</sup>
- Among patients in need of inpatient services, the mortality rate is 37%<sup>(3)</sup>

## AHD Current Implementation


- MSF-supported sites: Beira Central Hospital, Munhava and Ponta Gea with a referral-counter-referral flow
- CRAM – Alto Mae is a referral center on AHD supported by ITECH
- AHD package offered at José Macamo General Hospital as part of initial triage in emergency ward, with a referral/counter-referral with CRAM's outpatient care

(1) Médecins Sans Frontières. (2018). MSF HIV/TB clinical guide for primary care. Cape Town: MSF, p. 218.

(2) Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021.

(3) David Maman, Rapport Hospitalization CHK 2015/2017, Epicentre, 2017

# Implementation and Monitoring of AHD Package Rollout in COP21



## Updates - COP21

- Donor coordination: TA by PEPFAR and commodities by GF
- Trained providers at 26 sites and provincial teams
- CD4, CrAg, TB-LAM reagents in country, on-going site distribution
- Adjustments in CD4 network to improve access

## Next Steps - COP21

- Complete, intermediate & basic package at 27 sites starting at April
- Finalize SOP for documentation of AHD screening, diagnosis and treatment in patient clinic record
- Pilot an AHD specific clinic record form
- Finalize M&E procedures



*Kaposi Sarcoma treatment room*



*AHD ToT, Maputo Province, Sept '21*

# Advanced Disease Package of Services Offered in Mozambique

## Basic package – All sites

- Clinical evaluation
- CD4 and VL testing (for eligible patients)
- Opportunistic infections screening and test: Blood CrAg, TB-LAM and Xpert MTB/Rif
- Treatment of TB and other specific conditions
- Prophylaxis: TPT, CTZ, Cryptococcosis - fluconazole

## Intermediate package – District Hospitals

- Basic package
- Cerebrospinal fluid (CSF) CrAg test for patients with serum CrAg+
- Treatment of Cryptococcal meningitis
- Follow-up by more differentiated clinicians

## Advanced package – Central and Provincial Hospitals

- Intermediate package
- Treatment of Cryptococcal meningitis with advanced drugs
- Kaposi's sarcoma chemotherapy treatment

# Plans for AHD Implementation in COP 22

## COP22 Plans

- Expand advanced package to 3/4 additional sites per province
- Strengthen TA efforts for sites with advanced and intermediate packages
- Implement DISA POC at selected AHD sites to capture testing data

## GF Commodities & Equipment

- GF to maintain responsibility for AHD commodities
- Commodity shipment uncertainties negatively impact expansion plans
- 42 BD FACSPresto CD4 instruments to be installed by end of calendar year

## Program Monitoring

- Implementation of AHD specific clinic record form
- Reporting of standardized AHD indicators
- Technical assistance visits by central partner to all provinces



# HIV/TB COP22 Priorities

# TB/HIV Updates And Portfolio Overview

Continued strong performance in TB\_STAT and TB\_ART with low variability

TPT completion volumes, rates, and coverage of TX\_CURR are increasing rapidly but with notable variability


Integration of TB screening into COVID-19 national algorithms, and active revision of NTP instruments

Persistent gaps in TX\_TB screening cascade both in coverage and quality of TB screening for PLHIV, and M&E of presumptive TB cases

Ongoing challenges with the TB lab diagnostics, especially service maintenance of the GeneXpert network

Nationally 84% TB treatment coverage of estimated cases, but low rates of bacteriological confirmation (~35%)


# TB Notifications Remain Strong Despite COVID19



- Stable annual TB notifications vs decrease in TB notifications of 15-30% in many high-burden countries
- Modest decrease in notified pediatric TB from 13% to 11%

# TPT Completion Rates And Volumes Continue Climbing


Trend in TPT Completion Rates and Client Volumes



- Continued increase in total individuals that complete TPT by semester
- TPT completion rates have plateaued, but are approaching target of 90%
- Implementation of 3HP in two provinces and expansion plan in discussion, yet risk of oversupply of TPT nationally


# Persistent Variability In TPT Completion At Province And Partner Level

AJUDA Site TPT Completion Rates and Volumes for Province Level (2021 Q4)



# TPT Coverage Rates Of TX\_CURR Continue Climbing But Are Variable

Monthly Trend in TPT Coverage of TX\_CURR at AJUDA Sites




AJUDA Site Level Outlier Analysis of TPT Coverage (January 2022)



- **Increase in TPT Coverage among TX\_CURR at AJUDA sites from 0.7M/1.2M (55%) in Mar 2021 to 1M/1.4M (74%) in Jan 2022**
  - TPT coverage includes those who have completed or are actively on TPT out of TX\_CURR
  - 345K (24%) of TX\_CURR at AJUDA sites are still TPT Candidates and targeted for mop-up in COP21
  - There is still significant provincial/partner/site level variability – we will focus on underperforming sites in COP22

# The TB Screening Cascade Continues To Be A Challenge

TX\_TB Positive Screening Cascade (2021 Q4)



## Gaps


- Missing ~520,000 TB screening events in PLHIV at AJUDA sites annually
- Major variability by province in TX\_CURR not screened for TB (from 4 - 38%)
- Persistently low rates of documented TB testing, bacteriological confirmation of those tested
- Challenges with GeneXpert lab network, sample transport, and getting results into EPTS
- Only semesterly data and limited data points

## Solutions


- Enhanced TX\_TB monthly monitoring with new report
- Line lists of patients to better identify and follow up with clients that fall out of the cascade
- Support use of new innovations in TB case-finding (CXR, CAD and TB-LAM)
- If approved by MISAU, implement new presumptive TB registers to ensure appropriate evaluation
- Support new MOH TB/HIV cQI and mentoring strategy

# Persistent Gaps In TB Screening for PLHIV With Provincial And Site Level Variability

AJUDA Site TB Screening Rates for PLHIV at Province Level (2021 Q4)



# TB/HIV Priority Activities For COP22





Obrigado!